Damià Tormo


Managing partner and co-founder of Columbus Venture Partners, Damià has spent the last 15 years working in healthcare and the biopharmaceutical industry. He has focused on life science venture capital investing and company formation since 2010, where he focuses on private company investments in the biopharmaceutical, life science and medical technology sectors. He has founded several biotech companies such as Artax Biopharma Inc, Bioncotech Therapeutics SL, Restaura Biotech SL, or PTS. From 2010 to 2013 he was CEO of Bioncotech Therapeutics, an oncology clinical stage drug development company. Damia is currently on the Boards of Viralgen Vector Core, PolypeptideTherapeutic Solutions, Artax Biopharma, Highlight Therapeutics and Sanifit. Moreover, Damia is the President of Fundación Columbus, a non profit organization that facilitates acccess to advanced therapies for children with cancer and ultra-rare genetic diseases.

Before this, he was a researcher in different institutions such as the Uniklinik Bonn, University of Michigan or the Spanish National Cancer Center (CNIO). He has been awarded several prizes related to innovation and entrepreneurship, including TR35 from MIT, the Biogen Foundation Award or the Princess Girona Foundation Award.
Damia holds a MSc in Biological Sciences from the University of Valencia, a Master in Biotechnology Managment from IE Business School and earned his PhD in Immunology and Molecular Genetics from the Rheinische Friedrich-Wilhelms-Universität Bonn, Germany.